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measure, and for cases that could be 
seropositive but have lesions caused 
by agents other than yaws. Selection 
of appropriate settings and the rational 
use of serological and molecular tests 
during the yaws eradication project 
must be addressed through appropriate 
policy design that includes the routine 
practice of the health worker.
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Authors’ reply 
We thank Sapna Pahil and Kapil Goyal 
for their interest in our work. Our 
research has identified a previously 
unrecognised cause of skin ulcers in the 
tropics, namely Haemophilus ducreyi.1 
Although there had been several case 
reports implicating this organism 
as a causative agent of chronic skin 
ulceration, we show that this is indeed 
a very common pathogen in the tropics 
and that it can be a confusing factor in 
the diagnosis of yaws.
We share Pahil and Goyal’s view 
on the importance of laboratory 
conﬁ rmation of the cause of ulcerative 
skin lesions in individual settings. Our 
ﬁ ndings show that clinical diagnosis of 
the causes of skin ulcer is a challenge 
and requires laboratory evidence. The 
absence of useful serological testing 
and fastidious culture requirements 
for H ducreyi means a test is needed 
that can be done in settings with 
scarce resources. In this context, the 
development of a multiplex loop-
mediated isothermal amplification 
(LAMP) test that can simultaneously 
detect several causative agents of skin 
ulcer seen in children in the tropics, 
such as Treponema pallidum subsp. 
pertenue, Mycobacterium ulcerans, and 
H ducreyi, would be optimum.2,3 The 
widespread use of the LAMP test is 
restricted because it is expensive, at 
a cost of about US$4 per test, and it 
requires basic equipment and trained 
personnel. During a worldwide yaws 
eradication campaign, sustaining 
access to LAMP technology for all yaws 
programmes across Africa, Asia, and 
the south Paciﬁ c could be diﬃ  cult.
In the context of our present 
work that uses total community 
treatment with azithromycin for 
yaws eradication, we would support 
an empirical approach to treatment. 
Azithromycin is eﬀ ective for treatment 
of both H ducreyi and T p pertenue, so 
our mass treatment should be eﬀ ective 
for both causes of skin ulcer. H ducreyi 
isolates from skin infections in Samoa 
were susceptible to azithromycin, with 
minimum inhibitory concentrations 
of 0·012 mg/L.4 Furthermore, the 
tissue half-life of azithromycin is such 
that protection against reinfection 
with either organism should continue 
for many weeks after treatment. In 
well controlled studies, a 1 g dose 
of azithromycin protected against 
experimental H ducreyi infection for 
a mean period of about 2 months.5 
Because development of macrolide 
resistance requires only a single 
base-pair mutation, we agree with 
Sally Roberts and Susan Taylor6 that 
surveillance to monitor the appearance 
of resistance mutations is essential.
After mass treatment, in the 
setting of active case detection for 
identification of new yaws cases, a 
test such as LAMP might be useful. 
Although the WHO-endorsed DPP 
Syphilis Screen and Confirm Assay 
(Chembio, USA) allows improved 
determination of the yaws serological 
status of the patient in the field,7 
molecular assays must be used as an 
adjunct to serology because of the 
very high level of seropositivity in 
at-risk populations. Molecular assays 
should be used as a quality control 
